About DNA primase small subunit
DNA primase small subunit (PRIM1) is a protein
from Homo sapiens identified by UniProt accession
P49642, 420 residues long.
MolForge cross-references it against 0 known binders and
358 disease associations.
Target properties
| Protein name | DNA primase small subunit |
|---|
| UniProt accession | P49642 |
|---|
| Gene | PRIM1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 420 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (358)
Diseases linked to this target (Open Targets).
- microcephalic primordial dwarfism · score 0.62
- non-small cell lung carcinoma · score 0.60
- acute myeloid leukemia · score 0.60
- acute lymphoblastic leukemia · score 0.60
- pancreatic carcinoma · score 0.59
- chronic lymphocytic leukemia · score 0.59
- neoplasm · score 0.58
- ovarian carcinoma · score 0.57
- breast carcinoma · score 0.57
- adult acute lymphoblastic leukemia · score 0.56
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P49642-F1 | alphafold | PREDICTED | 92.70 | — |
Amino-acid sequence (420 residues)
METFDPTELP ELLKLYYRRL FPYSQYYRWL NYGGVIKNYF QHREFSFTLK DDIYIRYQSF NNQSDLEKEM QKMNPYKIDI GAVYSHRPNQ HNTVKLGAFQ AQEKELVFDI DMTDYDDVRR CCSSADICPK CWTLMTMAIR IIDRALKEDF GFKHRLWVYS GRRGVHCWVC DESVRKLSSA VRSGIVEYLS LVKGGQDVKK KVHLSEKIHP FIRKSINIIK KYFEEYALVN QDILENKESW DKILALVPET IHDELQQSFQ KSHNSLQRWE HLKKVASRYQ NNIKNDKYGP WLEWEIMLQY CFPRLDINVS KGINHLLKSP FSVHPKTGRI SVPIDLQKVD QFDPFTVPTI SFICRELDAI STNEEEKEEN EAESDVKHRT RDYKKTSLAP YVKVFEHFLE NLDKSRKGEL LKKSDLQKDF
Explore DNA primase small subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets